The Oncologic Drugs Advisory Committee (ODAC) decided 10-2 with one abstention that PD-1 inhibitors do not have a favorable risk/benefit profile in gastric/gastroesophageal junction (GEJ) cancers with ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...
BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...
ES-SCLC accounts for the majority of small-cell lung cancer diagnoses and is characterized by rapid progression and poor ...
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback